Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANOVA: Niraparib +/- Bevacizumab in Ovarian Cancer
NCT02354131Phase 2Completed
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Feb 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Niraparib Monotherapy with Niraparib + Bevacizumab (2 arms). Primary endpoint: Progression-Free Survival at 30 months. Started Feb 2015; status: completed.
02
Drugs
niraparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02354131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354131.